{"drugs":["Alpha-1 Proteinase Inhibitor Human","Aralast","Aralast NP","Glassia","Prolastin","Prolastin-C","Zemaira"],"mono":{"0":{"id":"490360-s-0","title":"Generic Names","mono":"Alpha-1 Proteinase Inhibitor Human"},"1":{"id":"490360-s-1","title":"Dosing and Indications","sub":{"0":{"id":"490360-s-1-4","title":"Adult Dosing","mono":"<b>Alpha-1-antitrypsin deficiency:<\/b> 60 mg\/kg IV infusion ONCE weekly "},"1":{"id":"490360-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in children "},"3":{"id":"490360-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Alpha-1-antitrypsin deficiency<br\/>"}}},"3":{"id":"490360-s-3","title":"Contraindications\/Warnings","sub":[{"id":"490360-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to alpha-1 proteinase inhibitor products<\/li><li>IgA deficient patients with antibodies against IgA<\/li><\/ul>"},{"id":"490360-s-3-10","title":"Precautions","mono":"<ul><li>IgA deficiency, selective or severe with known antibodies to IgA; increased risk of severe hypersensitivity and anaphylaxis; monitor vital signs continuously during infusion<\/li><li>risk of transmitting infectious agents (eg, Creutzfeldt-Jakob disease); derived from pooled human plasma<\/li><li>report possible infections from alpha-1 proteinase inhibitor to manufacturer for Aralast(TM) or Aralast-NP(TM) at 1-800-423-2090  or for Glassia(R) at 1-866-GLASSIA or the FDA 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"490360-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"490360-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"490360-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest discomfort (6%)<\/li><li><b>Hepatic:<\/b>Increased liver aminotransferase level (11.1%), Increased liver enzymes (6%)<\/li><li><b>Neurologic:<\/b>Dizziness (3% to 6%), Headache (0.7% to 9%)<\/li><li><b>Respiratory:<\/b>Cough (15%), Sinusitis (6%), Upper respiratory infection (12%)<\/li><\/ul><b>Serious<\/b><br\/><b>Respiratory:<\/b>Acute exacerbation of chronic obstructive pulmonary disease (12%)<br\/>"},"6":{"id":"490360-s-6","title":"Drug Name Info","sub":{"0":{"id":"490360-s-6-17","title":"US Trade Names","mono":"<ul><li>Aralast<\/li><li>Prolastin<\/li><li>Zemaira<\/li><li>Aralast NP<\/li><li>Prolastin-C<\/li><li>Glassia<\/li><\/ul>"},"2":{"id":"490360-s-6-19","title":"Class","mono":"Blood Modifier Agent<br\/>"},"3":{"id":"490360-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"490360-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"490360-s-7","title":"Mechanism Of Action","mono":"Alpha-1 proteinase inhibitor (alpha-1 PI) deficiency (also known as alpha 1-antitrypsin deficiency) is characterized by reduced levels of alpha-1 PI in the blood and lungs. Patients with severe alpha-1 PI deficiency have increased levels of neutrophil and neutrophil elastase levels in lung epithelial lining fluid. Alpha-1 PI (human) therapy augments the level of the deficient protein and theoretically corrects the imbalance between neutrophil elastase and protease inhibitors, which may protect the lower respiratory tract.<br\/>"},"8":{"id":"490360-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"490360-s-8-24","title":"Distribution","mono":"Vd: 3.2 to 5.6 L <br\/>"},"2":{"id":"490360-s-8-25","title":"Metabolism","mono":"Intravascular space: 33% (Gadek & Crystal, 1983)<br\/>"},"3":{"id":"490360-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance: 0.68 mL\/hr\/kg<\/li><li>Total body clearance: 862 to 940 mL\/day<\/li><\/ul>"},"4":{"id":"490360-s-8-27","title":"Elimination Half Life","mono":"4.5 to 5.9 days <br\/>"}}},"9":{"id":"490360-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>approved for IV use only<\/li><li>use within 3 hr after reconstitution; should be reconstituted at room temperature using the supplied transfer device and diluent<\/li><li>Prolastin(R): do not refrigerate after reconstitution<\/li><li>Zemaira(R) and Glassia(TM): administer using a 5-micron infusion filter<\/li><li>Aralast(TM), Aralast NP(TM) and Prolastin(R): a 20-micron filter should be used when transferring any reconstituted product into empty, intravenous containers<\/li><li>infuse at a maximum rate of 0.08 mL\/kg\/min for Aralast(TM), Aralast NP(TM), Zemaira(R), and Prolastin(R), or 0.04 mL\/kg\/min for Glassia(TM); if adverse events occur, the rate should be reduced or interrupted<\/li><\/ul>"},"10":{"id":"490360-s-10","title":"Monitoring","mono":"<ul><li>improvement in serum alpha-1 proteinase inhibitor levels is indicative of therapeutic response<\/li><li>slowed progression of emphysema or decrease in frequency, duration, or severity of pulmonary exacerbations may indicate efficacy<\/li><li>infusion rate; during administration<\/li><li>signs of hypersensitivity and\/or infusion-related reactions; during administration<\/li><li>vital signs; continuously throughout infusion<\/li><\/ul>"},"11":{"id":"490360-s-11","title":"How Supplied","mono":"<ul><li><b>Aralast NP<\/b><br\/>Intravenous Powder for Solution: 1 MG<br\/><\/li><li><b>Glassia<\/b><br\/>Intravenous Solution: 1 MG<br\/><\/li><li><b>Prolastin-C<\/b><br\/>Intravenous Powder for Solution: 1 MG<br\/><\/li><li><b>Zemaira<\/b><br\/>Intravenous Powder for Solution: 1 MG<br\/><\/li><\/ul>"},"13":{"id":"490360-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient of risk for transmission of infectious agents due to pooled human plasma product.<\/li><li>This drug may cause headaches and dizziness.<\/li><li>Instruct patient to report symptoms of hypersensitivity reactions.<\/li><\/ul>"}}}